Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information

Core Insights - Elite Pharmaceuticals, Inc. reported consolidated revenues of $36.3 million for the second quarter of fiscal year 2026, marking an increase of $17.4 million or approximately 92% compared to the same period in the previous fiscal year [2] - Income from operations reached $8.2 million, an increase of $4.7 million or approximately 136% year-over-year, primarily driven by sales of lisdexamfetamine products and strong growth in Elite's product lines [2] Financial Performance - The significant revenue growth of 92% is attributed to the successful launch of new products and overall strong performance in the company's product lines [2] - The increase in income from operations reflects improved operational efficiency and market demand for Elite's niche generic products [2] Conference Call Information - A conference call is scheduled for November 17, 2025, at 11:30 AM EST to discuss the financial results and recent business developments [3][4] - Stakeholders are encouraged to submit questions in advance of the call [3]